Hikal Ltd

HIKAL

₹207.63

₹-0.74 (-0.36%)

Closed · As of 26 Aug 3:30 pm

Pharmaceuticals - Indian - Bulk Drugs

Mkt Cap

₹2,562 Cr

P/E

-75.84

ROE

3.03%

ROCE

3.56%

Hikal Ltd

HIKALPharmaceuticals - Indian - Bulk Drugs

₹207.63₹-0.74 (-0.36%)

Closed · As of 26 Aug 3:30 pm

Market Cap

2,562 Cr

P/E Ratio

-75.84

ROE

3.03%

ROCE

3.56%

About Hikal Ltd

Hikal is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities.

Founded

1988

CEO

J Hiremath

Employees

3,595

Mumbai, India

About Hikal Ltd

Hikal is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities.

Founded:1988

CEO:J Hiremath

Employees:3,595

HQ:Mumbai, India

Finished Products

1Sale of Products

₹3,533.30Cr

2Service Income

₹78.86Cr

3Other Operating Revenue

₹19.35Cr

4Export Incentive

₹8.59Cr

5Sale of Scrap

₹4.30Cr

Raw Materials

1Raw Material Consumed

₹1,687.75Cr

Price Performance & Market EventsPrice Performance

Loading chart data…

Key Metrics

Trading & valuation snapshot

52W High

₹283

52W Low

₹146

Volume105.54K

Avg VolumeN/A

Beta1.52

Dividend Yield0.29%

Key Financial Ratios

Profitability, leverage & efficiency at a glance

P/E Ratio

-75.84x

Valuation

P/B Ratio

2.14x

Valuation

EPS

₹-2.74

Valuation

Dividend Yield

0.29%

Valuation

ROE

3.03%

Profitability

ROCE

3.56%

Profitability

Revenue by Segment

Contribution & growth by business line

Pharmaceutical

+6.2%62.8%

₹1,168.1 Cr

Crop Protection

+1.1%37.2%

₹691.7 Cr

Geographical Revenue Split

Domestic vs international exposure

Domestic

37.9%

International

62.1%

India37.9%

Europe28.5%

South East Asia16.1%

USA and Canada13.5%

Others4.1%

Strategic Relations

Collaborations, joint ventures & subsidiaries

Sumitomo Corporation

Japan

18.78% stake

Forensic Metrics

Financial health & earnings-quality indicators

Revenue Quality

N/A

Days Sales Outstanding

Leverage

0.57x

Debt-to-Equity

Earnings Quality

N/A

Cash Conversion Ratio

Efficiency

N/A

Asset Turnover

Earnings Quality

N/A

Accruals Ratio

Profitability

N/A

Gross Margin

Growth

-2.8%

Sales Growth

These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.